Avelumab, an anti-PD-L1 antibody, became the first FDA-approved agent for metastatic MCC in 2017 after the phase II JAVELIN Merkel 200 trial (NCT02155647) showed tumor regressions in chemotherapy-refractory patients [7,9]. Here, CD274 is linked to neoplasm.